GPR63

Across TCGA pan-cancer cohorts, GPR63 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GPR63 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher GPR63 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPR63 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCS, UCEC, and KIRC are the cancer types where GPR63 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	II,III,IV	0.001	0.616	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.440	.023	14	view →
KIRC	DFS	Median	All	0.252	0.796	.009	12	view →
LIHC	DFS	Median	All	0.209	0.550	<.001	9	view →
LUAD	OS	Median	All	0.579	0.835	<.001	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GPR63–UCS (OS)

Open the UCS breakdown →